Slaughter and May advised GE Healthcare on the transfer of development and marketing rights for four diagnostic imaging agents in Japan

Slaughter and May advised GE Healthcare on its agreement with Daiichi Sankyo for the return of the exclusive development and marketing rights to four diagnostic imaging products in Japan to GE Healthcare and the transfer of the associated marketing authorisations. The transfer is subject to customary regulatory approvals and closing conditions and is expected to complete in March 2020.

It is expected that Daiichi Sankyo will continue to distribute the products in Japan until March 2022 and Slaughter and May also advised on those transitional distribution arrangements.

Slaughter and May were supported by Nishimura & Asahi on matters of Japanese law.